ARKAY Therapeutics, Logo

(609) 362-6818

Follow Us:LinkedIn

Publications

Kumar, R. (2021) TriGlytza™: Clinical PoC for Counter-Regualtion of RAAS-AngII-Cox2-PGE2 Axis for Treatment and Mitigation of ARDS and MODS Associated with COVID-19. Published on Linkedin, October 5, 2021.  

Kumar, R. (2019) “Get Real and Get It Right With Type 2 Diabetes: It Is Time For A Paradigm Shift” published on LinkedIn, March 27, 2019.

Kumar, R. (2016) Anti-inflammatory Centric Drug Combination Lowers Non-fasting and Fasting Blood Glucose Levels in C57BL/6 DIO Mice with Insulin Resistance. Diabetes 65 (Suppl.1): A294. 2016-A-3237-Diabetes. 76th Scientific Sessions of the American Diabetes Association (June 10-14, 2016), New Orleans, LA.                  

Schwartz, S.S. et al. (2016) The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the ß-Cell-Centric Classification Schema. Diabetes Care 39:179–186.

Skyler, J.S. et al. (2017) Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes 66:241-255. DOI: 10.2337/db16-0806.

Seferovic, J.P. et al (2017) Effect of sacubitril/valsartan versus enalapril on glycemic control in patients with heart failure and diabetes: A post-hoc analysis from the PARADIGM-HF trial. THE LANCET Diabetes & Endocrinology. Published Online March 18, 2017.

Lu, C.H. et al. (2016) Additional Effect of Metformin and Celecoxib Against Lipid dysregulation and Adipose Tissue Inflammation in High-fat Fed Rats with Insulin Resistance and Fatty Liver. Eur. J. Pharmacol. 789: 60-67.

Nissen, S.E. et al. (2016) Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. New Engl. J. Med. 375(26): 2519-2529. DOI: 10.1056/NEJMoa1611593

Vinik, A.I. (2004) Inflammation: The Root of all Evil in Diabetes and Dysmetabolic Syndrome. (Create an account with login information at medscape.com to access the article)

Kidde, J. and Sahebkar, A. (2020) From Foe to Friend in COVID-19: Renin-Angiotensin Inhibitors. J. Infect. Dis. 

Wong, H. et al (2020) Celebrex adjuvant therapy on Corona disease 2019: An experimental study. Front. Pharmacol. Vol 11, Article 561674.

Tomera, K.M. et al. (2021) Hospitalized COVID-19 patients treated with Celecoxib and high dose of Famotidine adjuvant therapy show significant clinical responses. (Preprint publication). 

Duarte, M. et al. (2021) Telmisartan for treatment of covid-19 patients: An open multicenter randomized clinical trial. EClin. Med. 37, Article 100962.